

09/04/98  
jc540 U.S. PTO  
10-1082

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Date September 4, 1998  
Case Docket No. MIT 7150CIP(2)  
Express Mail No. EM500208769US

A

jc540 U.S. PTO  
09/148012  
09/04/98

Transmitted herewith for filing is the patent application of  
Inventors: Monty Krieger  
For: **SR-BI ANTAGONIST AND USE THEREOF AS CONTRACEPTIVES AND  
IN THE TREATMENT OF STEROIDAL OVERPRODUCTION**

Enclosed are:

One page of Abstract, 66 pages of Specification, 2 pages of claims, 6 sheets of informal drawings, 8 pages of Sequence Listing

- ☒ 6 sheets of informal drawings.
- ☐ An Assignment of the invention to \_\_\_\_\_
- ☐ A certified copy of a \_\_\_\_\_ application.
- ☒ An unexecuted Declaration
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27
- ☐ Request for Filing a Divisional Application under 37 CFR §1.60.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	18-20 =	0
INDEP CLAIMS	1-3 =	0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
RATE	FEE		RATE	FEE
	\$395	OR		\$790
x 11 =	\$	OR	x 22 =	\$ 0
x 41 =	\$	OR	x 82 =	\$ 0
x135 =	\$	OR	x270 =	\$
TOTAL	\$	OR	TOTAL	\$790

\* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

- ☐ Please charge my Deposit Account No. 01-2507 in the amount of \$ . A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$790.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.
  - ☒ Any additional filing fees required under 37 CFR 1.16.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
  - ☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
  - ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.

Respectfully submitted,

Robert A. Hodges, Reg. No. 41,074

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Monty Krieger

Serial No:

Express Mail Label No.

EM 500 208 769 US

Filed: September 4, 1998

Date of Deposit  
September 4, 1998

For: **SR-BI ANTAGONIST AND USE THEREOF AS CONTRACEPTIVES  
AND IN THE TREATMENT OF STEROIDAL OVERPRODUCTION**

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

EXPRESS MAIL TRANSMITTAL LETTER  
FOR PATENT APPLICATION AND CERTIFICATE OF MAILING

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Monty Krieger encloses for filing the attached patent application entitled "SR-BI ANTAGONIST AND USE THEREOF AS CONTRACEPTIVES AND IN THE TREATMENT OF STEROIDAL OVERPRODUCTION." The application includes one page of Abstract, 66 pages of Specification, 2 pages of claims, 6 sheets of informal drawings, 8 pages of Sequence Listing and unexecuted Declaration. A check in the amount of \$790.00 to cover the filing fee is also enclosed. An Assignment to Massachusetts Institute of Technology will be submitted shortly.

This application is being filed on September 4, 1998 by mailing the application to the Assistant Commissioner for

TITLE: SR-BI ANTAGONIST AND USE THEREOF AS CONTRACEPTIVES AND IN THE TREATMENT OF STEROIDAL OVERPRODUCTION"  
By: Monty Krieger  
EXPRESS MAIL TRANSMITTAL FOR PATENT APPLICATION

Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label No. appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(B).

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R. § 1.821-1.825. Pursuant to 37 C.F.R. § 1.821-1.825, applicants enclose a 3 & 1/2" diskette containing a computer-readable form of the Sequence Listing for the above-identified application. The application has a paper copy of the Sequence Listing incorporated therein.

I declare that the material on the diskette is identical to the paper copy of the Sequence Listing present in the above-identified application, that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.